Key Highlights

  • Third quarter 2026 total Revenue was $23.1 million, with RNS System revenue up 1.4%.
  • Full-year 2026 revenue guidance was revised to $91 million to $92 million.
  • Net loss narrowed to $3.3 million from $4.9 million in the prior-year quarter.
  • Remote Care was submitted to the FDA with a planned 180-day review cycle.

NeuroPace (NASDAQ:NPCE) reported third quarter 2026 financial results and revised its full-year revenue outlook on November 12, 2026. The company's Business centers on the RNS System, a responsive neurostimulation device used to treat people with epilepsy. Revenue grew only slightly from a year earlier, and management said the quarter fell below its own expectations. The company also provided updates on its regulatory filings and clinical programs, including a planned amendment to its idiopathic generalized epilepsy submission.

Revenue Performance and Guidance Revision

Total revenue for the third quarter was $23.1 million. RNS System revenue reached $22.9 million, an increase of 1.4% compared with the same period of 2025. Chief Executive Joel Becker said third-quarter revenue was below the company's expectations, with the shortfall concentrated in several of its largest accounts.

NeuroPace revised its full-year 2026 revenue guidance to a range of $91 million to $92 million. The company said it is focusing on commercial execution to return the business to historical growth rates, and it reported that fourth-quarter scheduled cases have begun to recover.

The company described the shortfall as concentrated in several of its largest accounts, and it said the issues were isolated to those accounts. Becker said the company's fourth-quarter scheduled procedures have begun to recover, which the company expects will help it move toward its revised full-year range.

Profitability and Operating Results

The net loss for the quarter was $3.3 million, compared with $4.9 million in the third quarter of 2025. Adjusted EBITDA was $0.4 million, reversing a loss of $1.3 million a year earlier. The company did not provide a detailed breakdown of operating expenses in its headline summary.

Management attributed the revenue shortfall to isolated account-level issues and to changes in its field organization that created more disruption than the company had anticipated. Becker said the company is taking steps to address those factors and maintains confidence in the underlying Demand for RNS therapy and its clinical outcomes.

The company's operating results were also affected by changes to its field organization, which management said created more disruption than it had planned for. NeuroPace did not provide a detailed expense breakdown in its headline summary, so the quarterly change in profitability reflects both revenue performance and cost management during the period.

Regulatory Submissions and Clinical Studies

NeuroPace completed a Submission Issue Request meeting with the FDA in October regarding its premarket approval supplement for idiopathic generalized epilepsy. It is incorporating the agency's feedback into an amendment and expects to submit that amendment around year-end. The company also submitted a premarket approval supplement for Remote Care, a feature designed to let physicians program the RNS System through telehealth, with a planned 180-day review period.

The company began enrolling patients in AURORA, a real-world evidence study intended to support an adolescent indication for patients aged 12 to 17 with drug-resistant focal epilepsy. Data collection is expected to finish in early 2027, followed by analysis and an FDA submission.

NeuroPace said the IGE amendment will incorporate feedback from the FDA's Submission Issue Request meeting. The company's regulatory calendar also includes the Remote Care review, which the company expects to run for 180 days, and the AURORA study, which will support any later decision on adolescent use.

Final Word

The third quarter shows NeuroPace reporting slight growth in its core RNS System revenue, a narrower loss and a revised full-year revenue range of $91 million to $92 million. The company attributes the shortfall to account-level and organizational factors that it says are being addressed. The timing of the IGE amendment, the Remote Care review and the AURORA data will shape the company's regulatory calendar over the coming months.